HAHande Arslan

Hande Arslan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hande Arslan has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Advanced Age on Posttransplant Infections and Outcomes in Solid Organ Transplant Recipients: A Multicenter Cohort Study

    by Sibel Altunisik Toplu, Vildan Avkan Oguz, Esra Tanyel, Imran Hasanoglu, Bengu Tatar, Tuba Turunc, Gule Cinar, Yesim Uygun Kizmaz, Gulnur Kul, Adem Kose, et al.

    Background: In recent years, with the aging population worldwide, the number of elderly undergoing solid organ transplantation has been steadily increasing. However, data on the effects of advanced age on infection characteristics and clinical outcomes in transplant recipients are limited. This study aimed to evaluate the effects of advanced age on infections and clinical outcomes in solid organ transplant recipients. Methods: This retrospective multicenter cohort study included patients who underwent solid organ transplantation at different transplant centers in Türkiye between 2003 and 2023 and were followed up for at least 1 year. Patients were divided into two age groups: ≥ 60 years and < 60 years. Demographic characteristics, laboratory parameters, infection episodes, and clinical outcomes were compared between the two age groups. Results: The study included 273 (27.7%) patients aged ≥ 60 years and 712 (72.3%) patients aged < 60 years, totaling 985 recipients. Male sex and liver transplantation were more common in the older age group ( p < 0.001). Hospital stay was significantly longer in patients aged ≥ 60 years ( p = 0.002). However, there was no difference between the two age groups in terms of time to first infection or number of infection episodes. The mortality rate in patients aged ≥ 60 years was 21.6%. The most common cause of death was bacterial infection, with carbapenem‐resistant pathogens detected in a substantial proportion of cases. Conclusions: Although infection incidence was similar across age groups, solid organ transplant recipients aged ≥ 60 years had higher mortality and longer hospital stays, highlighting the need for careful clinical monitoring in older transplant recipients. image

  • Open Access

    Exploring determinants in deciding the optimal antimicrobial dose in patients undergoing CRRT: a mixed-methods study

    by Tuğba Yanık Yalçın, Aysel Pehlivanlı, Fatma İrem Yeşiler, Helin Şahintürk, Özlem Azap, Hande Arslan, Bilgen Başgut, Pınar Zeyneloğlu

    Antimicrobial dosing in patients undergoing continuous renal replacement therapy (CRRT) is a clinical challenge. The study aimed to investigate the factors that influence appropriate antimicrobial doses in CRRT and to address gaps in current knowledge and practice. The mixed-method design involved two phases. For the quantitative phase, infectious disease, intensive care, and clinical pharmacy professionals completed a questionnaire assessing demographics and practice details, as well as their knowledge, attitudes, and practices on antibiotic dosing in CRRT. In the qualitative phase, online focus groups were conducted using a question schedule based on the Theoretical Domains Framework to explore challenges and expectations. A structured questionnaire was completed by 160 participants, most of whom were infectious disease specialists (61.3%) with over 10 years of experience (38.8%). Despite a high knowledge level of antimicrobial dosing during CRRT, the sieving coefficient was unclear at 74.4%. Although 96.3% reported adjusting doses, 78.8% lacked institutional guidelines, and 68.1% did not monitor drug levels. CRRT experience positively influenced knowledge and attitude scores, and different dosing practices were reported for meropenem, piperacillin-tazobactam, and vancomycin. Qualitative findings highlighted the need for standard guidelines and CRRT-specific training. Multidisciplinary collaboration and real-time monitoring of therapeutic drugs were emphasized. This study identifies key gaps in knowledge and practice regarding antimicrobial dosing in CRRT. Addressing these gaps requires targeted training programs, real-time drug monitoring, and the development of evidence-based dosing guidelines to enhance patient safety and antimicrobial efficacy. Future research should evaluate the impact of these interventions on clinical outcomes.


  • Open Access

    Enterokok Bakteriyemileri: Son 5 Yılda E. faecium ve E. faecalis’ in Direnç Profili ve Prognoza Etkisi

    by Nuran Sarı, Nurefşan Tuba Kurt, Ayşe Hande Arslan, Özlem Azap

    Amaç: Son yıllarda enterokok bakteriyemilerinin sıklığı ve mortaliteleri artmaktadır. Çalışmamızda enterokok bakteriyemilerinde son beş yıllık antimikrobiyallere direnç değişimleri, mortalite gelişimine etkisi olabilecek risk faktörleri araştırılarak, ampirik tedavilere ve hasta izlemlerine katkı sağlamak, ilerde yapılacak çalışmalara yol gösterici olabilmek amaçlanmıştır. Gereç ve Yöntemler: 2020-2024 tarihleri arasında 18 yaş üzeri enterokok bakteriyemileri kesitsel ve retrospektif olarak araştırılmıştır. Hastaların demografik verileri, komorbiditeleri, klinik bulguları, laboratuvar sonuçları, enfeksiyon odakları, yapılan invazif girişimler, etken dağılımları ve prognoz araştırılarak, SPSS 25.0 (IBM Corp., Armonk, NY, USA) programında analiz edilmiştir. Bulgular: 279 enterokok bakteriyemisinin, 140’ı (%50.2) kadın hastaydı. En sık etken E. faecium 161 (%57.7), yaş ortalaması 66.3±16.2 saptandı. E. faecium bakteriyemisi daha genç yaşlarda, cerrahi bölümlerde, sekonder kaynaklı, sağlık hizmeti ilişkili olarak görülmekteydi (p


  • Open Access

    P8.094: Assessment of Urinary Tract Infections Microbiologically in Kidney Transplant Recipients

    by Nuran Sari, Hande Arslan, Emre Karakaya, Mehmet Haberal

  • Open Access

    210.12: Booster Shots and Additional Doses for COVID-19 in Solid Organ Recipients

    by Cigdem Erol, Nuran Sari, Tugba Yanik Yalcin, Aydincan Akdur, Hande Arslan, Mehmet Haberal

  • Is There a Correlation Between the Cycle Threshold of SARS-CoV-2 RT-PCR and the Clinical Course of COVID-19?

    by Tuğba Yanık Yalçın, Çiğdem Erol, Saliha Aydın, Nuran Sarı, Gülbahar Darılmaz Yüce, Özlem Kurt Azap, Hande Arslan

  • Open Access

    Detection of COVID-19 by Machine Learning Using Routine Laboratory Tests

    by Hikmet Can Çubukçu, Deniz İlHan Topcu, Nilüfer Bayraktar, Murat Gülşen, Nuran Sarı, Ayşe Hande Arslan

    Objectives: The present study aimed to develop a clinical decision support tool to assist coronavirus disease 2019 (COVID-19) diagnoses with machine learning (ML) models using routine laboratory test results. Methods: We developed ML models using laboratory data (n = 1,391) composed of six clinical chemistry (CC) results, 14 CBC parameter results, and results of a severe acute respiratory syndrome coronavirus 2 real-time reverse transcription–polymerase chain reaction as a gold standard method. Four ML algorithms, including random forest (RF), gradient boosting (XGBoost), support vector machine (SVM), and logistic regression, were used to build eight ML models using CBC and a combination of CC and CBC parameters. Performance evaluation was conducted on the test data set and external validation data set from Brazil. Results: The accuracy values of all models ranged from 74% to 91%. The RF model trained from CC and CBC analytes showed the best performance on the present study’s data set (accuracy, 85.3%; sensitivity, 79.6%; specificity, 91.2%). The RF model trained from only CBC parameters detected COVID-19 cases with 82.8% accuracy. The best performance on the external validation data set belonged to the SVM model trained from CC and CBC parameters (accuracy, 91.18%; sensitivity, 100%; specificity, 84.21%). Conclusions: ML models presented in this study can be used as clinical decision support tools to contribute to physicians’ clinical judgment for COVID-19 diagnoses.


  • Open Access

    Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID‐19 infection: Prospective observational study

    by Tuğba Yanık Yalçın, Deniz İlhan Topçu, Özlem Doğan, Saliha Aydın, Nuran Sarı, Çiğdem Erol, Zeynep Ece Kuloğlu, Özlem Kurt Azap, Füsun Can, Hande Arslan

    Vaccines have been seen as the most important solution for ending the coronavirus disease 2019 (COVID‐19) pandemic. The aim of this study is to evaluate the antibody levels after inactivated virus vaccination. We included 148 healthcare workers (74 with prior COVID‐19 infection and 74 with not). They received two doses of inactivated virus vaccine (CoronaVac). Serum samples were prospectively collected three times (Days 0, 28, 56). We measured SARS‐CoV‐2 IgGsp antibodies quantitatively and neutralizing antibodies. After the first dose, antibody responses did not develop in 64.8% of the participants without prior COVID‐19 infection. All participants had developed antibody responses after the second dose. We observed that IgGsp antibody titers elicited by a single vaccine dose in participants with prior COVID‐19 infection were higher than after two doses of vaccine in participants without prior infection (geometric mean titer: 898 and 607 AU/ml). IgGsp antibodies, participants with prior COVID‐19 infection had higher antibody levels as geometric mean titers at all time points (p < 0.001). We also found a positive correlation between IgGsp antibody titers and neutralizing capacity (rs = 0.697, p < 0.001). Although people without prior COVID‐19 infection should complete their vaccination protocol, the adequacy of a single dose of vaccine is still in question for individuals with prior COVID‐19. New methods are needed to measure the duration of protection of vaccines and their effectiveness against variants as the world is vaccinated. We believe quantitative IgGsp values may reflect the neutralization capacity of some vaccines.